Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 10, 2002, Pages 1761-1770

  Yacyshyn, B R ^a,g   Barish, C ^b   Goff, J ^c   Dalke, D ^d   Gaspari, M ^e   Yu, R ^f   Tami, J ^f   Dorr, F A ^f   Sewell, K L ^f  

^a UNIVERSITY OF ALBERTA   (Canada)

^b WAKE RESEARCH ASSOCIATES   (United States)

^c Western States Clinical Research   (United States)

^d Gastroenterology Specialists   (United States)

^e Carolina Digestive Health Associates   (United States)

^f ISIS PHARMACEUTICALS   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FEVER; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; VOMITING;

ADOLESCENT; ADULT; AREA UNDER CURVE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; REMISSION INDUCTION; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 0036790088     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01341.x     Document Type: Article

References (51)

1. Dustin ML, Rothlein R, Bhan AK, et al. Induction by IL-1 and interferon: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 1986; 137: 245-54.
2. Rothlein R, Dustin ML, Marlin SD, Springer TA. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 1986: 137: 1270-4.
3. Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function associated antigen-1 (LFA-1). Cell 1987; 51: 813-9.
4. Diamond MS, Staunton DE, deFougerolles AR, et al. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol 1990; 111: 3129-39.
5. Furie MB, Tancinco MCA, Smith CW. Monoclonal antibodies to leukocyte chemoattractant-stimulated neutrophil transendothelial migration in vitro. Blood 1991; 78: 2089-97.
6. Oppenheimer-Marks N, Davis LS, Bogue DT, et al. Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes. J Immunol 1991; 147: 2913-21.
7. Van Seventer GA, Shimizu Y, Horgan KJH, Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 1990; 144: 4579-86.
8. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999; 285: 221-7.
9. Makgoba MW, Sanders ME, Ginther Luce GE, et al. Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol 1988; 18: 637-40.
10. Allavena P, Paganin C, Zhou D, et al. Interleukin-12 is chemotactic for natural killer cells and stimulates their interaction with vascular endothelium. Blood 1994; 84: 2261-8.
11. Entman ML, Youker K, Shoji T, et al. Neutrophil induced oxidative injury of cardiac myocytes. J Clin Invest 1992; 90: 1335-45.
12. To SS, Newman PM, Hyland MJ, et al. Regulation of adhesion molecule expression by human synovial microvascular endothelial cells in vitro. Arthritis Rheum 1996; 39: 467-77.
13. Beutler BR. The role of tumor necrosis factor in health and disease. Arthritis Rheum 1999; 26(Suppl 57): 16-21.
14. Levine DS. Clinical features and complications of Crohn's disease. In: Targan S, Shanahan F, eds. Inflammatory Bowel Disease: From Bench to Bedside. Baltimore: Williams & Wilkins, 1993: 296-316.
15. Bernstein CN, Sargent M. Gallatin WM. Beta 2 integrin/ICAM expression in Crohn's disease. Clin Immunol Immunopathol 1998; 86: 147-60.
16. Vainer B. Nielsen OH, Horn T. Comparative studies of the colonic in situ expression of ICAM-1, -2, and -3, beta 2 integrins (LFA-1, Mac-1, and p150, 95), and PECAM-1 in ulcerative colitis and Crohn's disease. Am J Surg Pathol 2000; 24: 1115-24.
17. Pooley N, Ghosh L, Sharon P. Up-regulation of E-selectin and ICAM-1 differs between Crohn's disease and ulcerative colitis. Dig Dis Sci 1995; 40: 219-25.
18. Souza HS, Elia CC. Spencer J, MacDonald TT. Expression of lymphocyte-endothelial receptor-ligand pairs, α4 β7/MAd-CAM-1 and OX40/OX 40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut 1999; 45: 856-63.
19. Musso A, Condon TP, West GA, et al. Regulation of ICAM-1 mediated fibroblast-T cell reciprocal interaction: implications for modulation of gut inflammation. Gastroenterology 1999; 117: 546-56.
20. Yacyshyn BR, Lazarovits A, Tsai V, Matejko K. Crohn's disease, ulcerative colitis, and normal intestinal lymphocytes express integrins in dissimilar patterns. Gastroenterology 1994; 107: 1364-71.
21. Von Andrian UH, Mackay CR. T cell function and migration: two sides of the same coin. N Eng J Med 2000; 343: 1020-34.
22. Liu ZX, Hiwatashi N, Noguchi M, Toyota T. Increased expression of costimulatory molecules on peripheral blood monocytes in patients with Crohn's disease. Scand J Gastroenterol 1997; 32: 1241-6.
23. Vainer B, Nielsen OH. Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease. Clin Exp Immunol 2000; 121: 242-7.
24. Bennett CF, Condon TP, Grimm S, et al. Inhibition of endothelial cell leukocyte adhesion molecule expression with antisense oligonucleotides. J Immunol 1994; 152: 3530-41.
25. Baker BF, Monia BP. Novel mechanisms for antisense-mediated regulation of gene expression. Biochim Biophys Acta 1999; 1489: 3-18.
26. Wu H, Lima WF, Crooke ST. Properties of cloned and expressed human RNase H1. J Biol Chem 1999; 274: 28 270-8.
27. Crooke ST. Molecular mechanisms of antisense drugs: human RNase H. Antisense Nucl Acid Drug Devel 1999; 9: 377-9.
28. Henry SP, Templin MV, Gillett N, et al. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicol Pathol 1999; 27: 95-100.
29. Mielo ME, Bennett CF, Miller BE, Welch DR. Enhanced metastatic ability of TNF-α treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (CD54) antisense oligonucleotides. Exp Cell Res 1994; 214: 231-41.
30. Nestle FO, Mitra RS, Bennett CF, et al. Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J Invest Dermatol 1994; 103: 569-75.
31. Stepkowski SM, Tu Y, Condon TP, Bennett CF. Blocking of heart allograft rejection by ICAM-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J Immunol 1994; 153: 5336-46.
32. Kumasaka T, Quinlan WM, Doyle NA, et al. The role of ICAM-1 in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice. J Clin Invest 1996; 97: 2362-9.
33. Bennett CF, Kornbrust D, Henry S, et al. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J Pharmacol Exp Ther 1997; 280: 988-1000.
34. Myers KJ, Murthy S, Flanigan A, et al. Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis. J Pharmacol Exp Ther 2002 in press.
35. Bowen-Yacyshyn MB, Bennett CF, Nation N, et al. Amelioration of chronic and spontaneous intestinal inflammation with an antisense oligonucleotide (ISIS 9125) to ICAM-1 in the HLA-B27/β2 microglobulin transgenic rat model. J Pharmacol Exp Ther 2002 in press.
36. Glover J, Leeds JM, Mant TGK, et al. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligonucleotide (ISIS 2302). J Pharmacol Exp Ther 1997; 282: 1173-80.
37. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998; 114: 1133-42. Erratum. Gastroenterology 2001; 121: 747.
38. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo-controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302) in active, steroid-dependent Crohn's disease. Gut 2002; 1: 36-41.
39. Best WR. Bectel JM. Singleton JW. Kern F. Derived values of the eight coefficients of the Crohn's Disease Activity Index. Gastroenterology 1979: 77: 483-6.
40. Leeds JM. Graham MJ. Truong L, Cummins LL. Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem 1996; 235: 36-43.
41. Yu RZ. Baker B. Chappell A. et al. Development of an ultra-sensitive non-competitive ELISA hybridization-ligation assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 2002; 304: 19-25.
42. Phillips JA, Craig SJ, Bayley D, et al. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem Pharmacol 1997; 54: 657-68.
43. Sheehan JP. Phan TM. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry 2001: 40: 4980-9.
44. Hamamoto N, Maemura K. Hirata I, et al. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules ELAM-1 or ICAM-1. Clin Exp Immunol 1999; 117: 462-8.
45. Iigo Y. Takashi T. Tamatani T, et al. ICAM-1 dependent pathway is critically involved in the pathogenesis of adjuvant arthritis in rats. J Immunol 1991; 147(12): 4167-71.
46. Gottlieb A. Krueger JG. Bright R, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000; 42: 428-35.
47. Kavanaugh AF. Davis LS, Schulze-Koops H, Lipsky PE. A phase I/II open label study of the safety and efficacy of an anti-intercellular adhesion molecule 1 monoclonal antibody in early rheumatoid arthritis. J Rheumatol 1996: 23: 1338-44.
48. Davis LS, Kavanaugh AF, Nichols LA, Lipsky PE. Induction of persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis. J Immunol 1995; 154: 3525-37.
49. Kavanaugh AF. Schulze-Koops H, Davis LS, Lipsky PE. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum 1997; 40: 849-53.
50. Henry SP, Giclas PC, Leeds J. et al. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 1997; 281: 810-6.
51. Maksymowych WP, Blackburn WD, Tami JA. Shanahan WR. A randomized, placebo controlled trial of an anti-sense oligodeoxynucleotide to ICAM-1 in the treatment of severe rheumatoid arthritis. J Rheumatol 2002; 29: 447-53.